BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.

/PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce has completed the acquisition...

Related Keywords

United Kingdom ,Canada ,Frankfurt ,Brandenburg ,Germany ,United States ,Spain ,Vancouver ,British Columbia ,British ,Canadian ,Kenneth Kovan ,Biovaxys Or Company ,Horizon Technology Finance Corporation ,Biovaxys Technology Corp ,Prnewswire Biovaxys Technology Corp ,Immunovaccine Technologies Inc ,Vaxys Technology ,Asset Purchase Agreement ,Companie Creditors Arrangement Act ,Biovaxys President ,Chief Operating Officer Kenneth Kovan ,Relapsed Refractory Diffuse Largeb Cell Lymphoma ,Frankfurt Bourse ,